The Cancer Gene Therapy Market size was valued at $1.4 billion in 2020, and is estimated to reach $11.4 billion by 2030, growing at a CAGR of 23.3% from 2021 to 2030.
Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. Owing to the high success rate during the preclinical and clinical trials, cancer gene therapy has gained popularity. There are many techniques used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or the inactivation of the gene whose function is abnormal. Cancer gene therapy is an approach to cancer treatment, where genetically engineered vectors such as viruses are used to transfer or replace a mutated gene (that is causing cancer) with a healthy gene. This technique can be used for both the prevention and treatment of disease. The most commonly used techniques for the treatment using cancer gene therapy includes oncolytic virotherapy, gene transfer, and gene-induced immunotherapy.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
- Bristol Myers Squibb Co.
- Novartis
- Amgen Inc.
- Glaxosmithkline PLC
- Kayropharma Therapeutics
- Gilead Sciences
- Adapta Immue
- Genulex Corporation
- SynerGene Therapeutics
- shanghai sunway biotech
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/2605
๐๐๐ญ ๐๐ฉ ๐๐จ ๐๐% ๐๐ข๐ฌ๐๐จ๐ฎ๐ง๐ญ, ๐๐ข๐ฅ๐ฅ ๐ญ๐ก๐ ๐๐๐ญ๐ ๐๐๐ญ๐ก ๐จ๐ ๐๐ฎ๐ ๐ฎ๐ฌ๐ญ ๐๐๐๐.
๐๐ผ๐๐ถ๐ฑ-๐ญ๐ต ๐ฆ๐ฐ๐ฒ๐ป๐ฎ๐ฟ๐ถ๐ผ:
The COVID-19 pandemic had a negative impact on the cancer gene therapy market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types – breast, colorectal, lung, pancreatic, gastric, and oesophageal cancers. Moreover, the Centres for Disease Control and Prevention (CDC) &many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and to secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the cancer gene therapy market. However, the situation is expected to gradually improve.
๐
๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/2605
๐๐๐ ๐
๐๐๐๐๐๐๐ ๐๐
๐๐๐ ๐๐๐๐๐
- By therapy, gene-induced immunotherapy was the highest contributor to the Cancer Gene Therapy Market size in 2020.
- By end-user, the hospital segment dominated the market in 2020 and is expected to continue this trend during the forecast period.
- Region-wise, North America garnered the largest revenue share in 2020; however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
By therapy segment, the gene induced immunotherapy segment is the largest contributor to the market growth and the gene transfer therapy segment is anticipated to be a lucrative market due to the positive results of these therapies during the preclinical and clinical trials for the treatment of cancer.
By end-user, the hospital segment is the largest contributor to the market growth. Owing to the increase in the prevalence of cancer worldwide and the surge in regulatory approval of gene therapy for cancer are key factors that foster the Cancer Gene Therapy Market growth.
By region, North America accounted for the maximum Cancer Gene Therapy Market share in 2020, owing to the high prevalence rate of cancer, presence of high disposable income, and high funding for R&D activities associated with cancer gene therapy. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to a rise in the incidence rate of cancer, an increase in a government initiative to improve healthcare infrastructure, and owing to rise in the number of people prone to various chronic diseases. In addition, approval and launch of cancer gene therapy products can positively influence market expansion inย developed countries, such as Japan, Australia, and New Zealand are the major factorsย for the growth of the cancer gene therapy market.
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com